Review



voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen  (Gilead Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Gilead Sciences voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen
    Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
    Voxilaprevir Hcv Ns3 4a Protease Inhibitor Chronic Hcv After Selected Prior Daa Failure Us Fda Approved In The Fixed Dose Vosevi Rescue Regimen, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 178 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Vosevi/pmc13748950-6-0-17
    Average 97 stars, based on 178 article reviews
    voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects"

    Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

    Journal: MedComm

    doi: 10.1002/mco2.71024

    Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
    Figure Legend Snippet: Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.

    Techniques Used: Protease Inhibitor

    Related Articles

    Immunopeptidomics:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Modification:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Variant Assay:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Selection:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Article Title:
    Article Snippet: .. Reference ID: 4217839 Uni‐Review– NDA 210251 Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC ‐ BIKTARVY® 58 6.2.2 Dose Selection, Population Pharmacokinetics and Pharmacodynamics Dose selection Dose selection of BIC for the Phase 3 trial was based on a dose‐ranging monotherapy study (GS‐US‐141‐1219) and a relative bioavailability study (GS‐US‐141‐1233). ..

    Article Title: Pan-genotypic agents against influenza virus and methods of using the same
    Article Snippet: .. Susceptibility of Influenza Viruses to Oseltamivir and LNA9, after Serial Passaging in the Presence of Drug: Drug Selection Experiment Oseltamivir (Tamiflu) is the most widely used and stockpiled neuraminidase inhibitor (NAI) on the market. ..

    Article Title: Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers
    Article Snippet: Influenza A virus (Orthomyxoviridae) , Neuraminidase inhibitors (NAIs): oseltamivir, zanamivir; capdependent endonuclease inhibitor: baloxavir marboxil , NA: H275Y (N1 numbering); PA endonuclease: I38T/M/F , Reduced reduction in symptom duration and viral shedding; concern about transmission competent resistant strains in high risk settings. , [ – ] . .. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (Coronaviridae) , RNA‐dependent RNA polymerase (RdRp) inhibitors: remdesivir; oral RdRp‐targeting agent: molnupiravir; 3CL protease inhibitor: nirmatrelvir (in Paxlovid); monoclonal antibodies (e.g., earlier agents now largely inactive) , RdRp targeting: E802D, C799F, several others under selection; spike protein targeting (mAbs): many S domain mutations (e.g., E484K, N501Y related lineages that evade certain antibodies) , Potential for reduced drug susceptibility and escape from neutralizing antibodies; particular concern in immunocompromised hosts receiving prolonged therapy. , [ , ] . .. Hepatitis C virus (Flaviviridae) , Directacting antivirals (DAAs): NS3/4A protease inhibitors (e.g., glecaprevir, voxilaprevir), NS5A inhibitors (e.g., ledipasvir, velpatasvir), NS5B polymerase inhibitors (e.g., sofosbuvir) , NS3/4A: A156T/V, D168A/V; NS5A: Y93H/N, L31M/V; NS5B: S282T (sofosbuvir selected) , Most modern DAA‐based regimens retain high SVR, but selected resistance‐associated substitutions can reduce response in retreatment or complex genotypes; need for genotype tailored salvage regimens. , [ ] .

    Article Title:
    Article Snippet: .. Section 1, Indication and Usage: In general, the review team agrees with the proposed indication for Stribild, although the language regarding appropriate patient selection will include only those who are HIV-1 treatment naïve. .. Only treatment naïve subjects were evaluated in the Stribild clinical trials and resistance testing was available for all subjects at baseline.

    Article Title:
    Article Snippet: .. Dose Selection: SOF 400 mg is the approved marketed dose of SOF (Sovaldi®) for the treatment of HCV infection and, as such, was selected for coformulation with VEL in an FDC tablet for evaluation in the SOF/VEL development program. ..

    Article Title:
    Article Snippet: .. These substitutions included those detected in the resistance selection experiments, detected in the STRIBILD-treatment failure isolates in Studies 102, 103, and 104, and known to be associated with RAL resistance: H51Y, T66A/I/K, L68I/V, V72I, E92G/Q, T97A, F121Y, E138A/K, G140S, Y143H/R, P145S, Q146I/K/L/P/R, S147G, Q148H/K/R, S153F/Y, N155H/S, E157Q, G163K/R, S230R, N232D, and R263K. ..

    Membrane:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Generated:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Imaging:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Clinical Proteomics:

    Article Title: A Membrane-Retained DNA Aptamer Promotes Intracellular Platinum Accumulation and Chemosensitization in Ovarian Cancer.
    Article Snippet: .. Aptamers, short single-stranded DNA or RNA oligonucleotides selected through systematic evolution of ligands by exponential enrichment (SELEX), have emerged as a versatile class of molecular recognition agents.11−13 Compared with conventional antibodies, aptamers possess distinct advantages, such as low immunogenicity, ease of chemical modification, rapid tissue penetration, and scalable synthesis.14−16 CellSELEX, a SELEX variant employing intact living cells as targets, enables the selection of aptamers against native membrane proteins without prior knowledge of the molecular target.17−19 Aptamers generated by Cell-SELEX have shown high potential in diagnostics and therapeutics.20−22 For example, Sgc8, selected against protein tyrosine kinase 7 (PTK7), has been widely used for tumor imaging and targeted drug delivery .23,24 In addition, AS1411, a nucleolin-binding DNA aptamer, has entered phase II clinical trials for cancer therapy,25 while pegaptanib (Macugen), an RNA aptamer against VEGF165, has been approved for the treatment of agerelated macular degeneration.26 Although these advances Received: August 25, 2025 Revised: December 17, 2025 Accepted: December 21, 2025 © XXXX The Authors. ..

    Drug discovery:

    Article Title:
    Article Snippet: .. Reference ID: 4217839 Uni‐Review– NDA 210251 Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC ‐ BIKTARVY® 58 6.2.2 Dose Selection, Population Pharmacokinetics and Pharmacodynamics Dose selection Dose selection of BIC for the Phase 3 trial was based on a dose‐ranging monotherapy study (GS‐US‐141‐1219) and a relative bioavailability study (GS‐US‐141‐1233). ..

    Passaging:

    Article Title: Pan-genotypic agents against influenza virus and methods of using the same
    Article Snippet: .. Susceptibility of Influenza Viruses to Oseltamivir and LNA9, after Serial Passaging in the Presence of Drug: Drug Selection Experiment Oseltamivir (Tamiflu) is the most widely used and stockpiled neuraminidase inhibitor (NAI) on the market. ..

    Protease Inhibitor:

    Article Title: Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers
    Article Snippet: Influenza A virus (Orthomyxoviridae) , Neuraminidase inhibitors (NAIs): oseltamivir, zanamivir; capdependent endonuclease inhibitor: baloxavir marboxil , NA: H275Y (N1 numbering); PA endonuclease: I38T/M/F , Reduced reduction in symptom duration and viral shedding; concern about transmission competent resistant strains in high risk settings. , [ – ] . .. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (Coronaviridae) , RNA‐dependent RNA polymerase (RdRp) inhibitors: remdesivir; oral RdRp‐targeting agent: molnupiravir; 3CL protease inhibitor: nirmatrelvir (in Paxlovid); monoclonal antibodies (e.g., earlier agents now largely inactive) , RdRp targeting: E802D, C799F, several others under selection; spike protein targeting (mAbs): many S domain mutations (e.g., E484K, N501Y related lineages that evade certain antibodies) , Potential for reduced drug susceptibility and escape from neutralizing antibodies; particular concern in immunocompromised hosts receiving prolonged therapy. , [ , ] . .. Hepatitis C virus (Flaviviridae) , Directacting antivirals (DAAs): NS3/4A protease inhibitors (e.g., glecaprevir, voxilaprevir), NS5A inhibitors (e.g., ledipasvir, velpatasvir), NS5B polymerase inhibitors (e.g., sofosbuvir) , NS3/4A: A156T/V, D168A/V; NS5A: Y93H/N, L31M/V; NS5B: S282T (sofosbuvir selected) , Most modern DAA‐based regimens retain high SVR, but selected resistance‐associated substitutions can reduce response in retreatment or complex genotypes; need for genotype tailored salvage regimens. , [ ] .

    Bioprocessing:

    Article Title: Trends, Gaps, and Challenges in Antiviral Resistance: A Bibliometric Analysis and Narrative Synthesis of Key Viruses, Resistance Mechanisms, and Drivers
    Article Snippet: Influenza A virus (Orthomyxoviridae) , Neuraminidase inhibitors (NAIs): oseltamivir, zanamivir; capdependent endonuclease inhibitor: baloxavir marboxil , NA: H275Y (N1 numbering); PA endonuclease: I38T/M/F , Reduced reduction in symptom duration and viral shedding; concern about transmission competent resistant strains in high risk settings. , [ – ] . .. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (Coronaviridae) , RNA‐dependent RNA polymerase (RdRp) inhibitors: remdesivir; oral RdRp‐targeting agent: molnupiravir; 3CL protease inhibitor: nirmatrelvir (in Paxlovid); monoclonal antibodies (e.g., earlier agents now largely inactive) , RdRp targeting: E802D, C799F, several others under selection; spike protein targeting (mAbs): many S domain mutations (e.g., E484K, N501Y related lineages that evade certain antibodies) , Potential for reduced drug susceptibility and escape from neutralizing antibodies; particular concern in immunocompromised hosts receiving prolonged therapy. , [ , ] . .. Hepatitis C virus (Flaviviridae) , Directacting antivirals (DAAs): NS3/4A protease inhibitors (e.g., glecaprevir, voxilaprevir), NS5A inhibitors (e.g., ledipasvir, velpatasvir), NS5B polymerase inhibitors (e.g., sofosbuvir) , NS3/4A: A156T/V, D168A/V; NS5A: Y93H/N, L31M/V; NS5B: S282T (sofosbuvir selected) , Most modern DAA‐based regimens retain high SVR, but selected resistance‐associated substitutions can reduce response in retreatment or complex genotypes; need for genotype tailored salvage regimens. , [ ] .

    Infection:

    Article Title:
    Article Snippet: .. Dose Selection: SOF 400 mg is the approved marketed dose of SOF (Sovaldi®) for the treatment of HCV infection and, as such, was selected for coformulation with VEL in an FDC tablet for evaluation in the SOF/VEL development program. ..



    Similar Products

    90
    Thermo Fisher orion calcium-selective electrode
    Orion Calcium Selective Electrode, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/10__22175_slash_mmb__17760-93-36-46
    Average 90 stars, based on 1 article reviews
    orion calcium-selective electrode - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Agilent technologies 5975-mass selection detector
    5975 Mass Selection Detector, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/10__22175_slash_mmb__17751-111-18-21
    Average 90 stars, based on 1 article reviews
    5975-mass selection detector - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher calcium-selective electrode
    Calcium Selective Electrode, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/calcium+selective+electrode/10__22175_slash_mmb__17760-93-38-46
    Average 90 stars, based on 1 article reviews
    calcium-selective electrode - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    Thermo Fisher amphotericin b
    Amphotericin B, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Oxoid+CCDA+Selective+Supplement/pmc13636059-214-25-27
    Average 94 stars, based on 1 article reviews
    amphotericin b - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    R&D Systems fetal bovine serum
    Fetal Bovine Serum, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Fetal+Bovine+Serum+-+Premium+Select%2C+Heat+Inactivated/pmc13754023-237-29-33
    Average 95 stars, based on 1 article reviews
    fetal bovine serum - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    99
    InvivoGen puromycin selection
    Puromycin Selection, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Puromycin/pm42976857-256-13-17
    Average 99 stars, based on 1 article reviews
    puromycin selection - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Zymo Research dna clean and concentrator kit
    Dna Clean And Concentrator Kit, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Select-a-Size+DNA+Clean+%26+Concentrator+Kit/pmc13748974-47-25-30
    Average 99 stars, based on 1 article reviews
    dna clean and concentrator kit - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    92
    MedChemExpress selective gsk 3α β inhibitors brd0705 cat
    Selective Gsk 3α β Inhibitors Brd0705 Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/BRD0705/pmc13746373-59-0-18
    Average 92 stars, based on 1 article reviews
    selective gsk 3α β inhibitors brd0705 cat - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    97
    Gilead Sciences voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen
    Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
    Voxilaprevir Hcv Ns3 4a Protease Inhibitor Chronic Hcv After Selected Prior Daa Failure Us Fda Approved In The Fixed Dose Vosevi Rescue Regimen, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/Vosevi/pmc13748950-6-0-17
    Average 97 stars, based on 1 article reviews
    voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    99
    Gilead Sciences narrow selectivity margin between fungal and host membrane sterols
    Previously abandoned antimicrobial agents: historical role, cause of decline, current status, and nanotechnology‐relevant design requirements.
    Narrow Selectivity Margin Between Fungal And Host Membrane Sterols, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/selection/AmBisome/pmc13746107-7-54-80
    Average 99 stars, based on 1 article reviews
    narrow selectivity margin between fungal and host membrane sterols - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    Image Search Results


    Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.

    Journal: MedComm

    Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

    doi: 10.1002/mco2.71024

    Figure Lengend Snippet: Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.

    Article Snippet: Voxilaprevir HCV NS3/4A protease inhibitor; chronic HCV after selected prior DAA failure; US FDA‐approved in the fixed‐dose Vosevi rescue regimen , C 40 H 52 F 4 N 6 O 9 S; CID 89921642 , Nirmatrelvir Covalent reversible SARS‐CoV‐2 Mpro/3CLpro inhibitor; COVID‐19; US FDA‐approved for eligible high‐risk adults only as nirmatrelvir/ritonavir (Paxlovid); pediatric use remains under EUA , C 23 H 32 F 3 N 5 O 4 ; CID 155903259.

    Techniques: Protease Inhibitor

    Previously abandoned antimicrobial agents: historical role, cause of decline, current status, and nanotechnology‐relevant design requirements.

    Journal: BioMed Research International

    Article Title: Nanotechnology as a Catalyst for Reintroducing Abandoned or Therapeutically Constrained Antimicrobial Agents: Opportunities and Translational Challenges

    doi: 10.1155/bmri/9486547

    Figure Lengend Snippet: Previously abandoned antimicrobial agents: historical role, cause of decline, current status, and nanotechnology‐relevant design requirements.

    Article Snippet: Amphotericin B – polyene , Isolated from Streptomyces nodosus ; introduced clinically in the late 1950s and remained the principal broad‐spectrum systemic antifungal for several decades (gold standard) despite severe infusion‐related toxicity. , Residual affinity for mammalian cholesterol alongside its target, fungal ergosterol, forms pores in renal tubular membranes at clinically active doses. , Narrow selectivity margin between fungal and host membrane sterols. , Retained as first‐line systemic therapy for invasive fungal infection, but almost exclusively in lipid‐based/liposomal formulations (e.g., AmBisome) that have already substantially reduced, though not eliminated, nephrotoxicity since the 1990s. , Further refinement of lipid‐based reformulation—the clearest existing proof‐of‐concept that nanocarrier encapsulation can rescue an abandoned‐by‐toxicity agent, and a template for other agents in this table. , [ ]; [ ]; [ ]; [ ] .

    Techniques: Nanotechnology, Isolation, Infection, Activity Assay, Toxicity, Membrane, Preserving, Tissue, Concentration Assay, Glycoproteomics, Purification, Filtration, Encapsulation, Formulation, Bacteria, Ointment, In Vitro, Produced